Register Interest

Novapep

Annual global sales of inflammatory skin disorders and irritable bowel syndrome drugs are in excess of $25 billion, yet there is an unmet medical need in these diseases.   Novapep, together with its shareholder - the University of Sydney, is developing cost-effective treatments which are attracting the interest of large pharma companies.